Faculty profile

Scott Tyldesley

ResearcherUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Scott Tyldesley

Researcher

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
26 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

115

Publications

118

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Biomarkers Cost-Effectiveness/Cost-Utility Metastatic Cancers Oligometastatic Disease/State Overall Survival Progression-Free Survival Quality Of Life Quality-Adjusted Life Years

Latest papers

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.
International journal of radiation oncology, biology, physics · 2026
NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.
European urology oncology · 2026
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
International journal of radiation oncology, biology, physics · 2026

All 115 publications

Latest funding

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
CIHR · 2019 · Principal investigator
$699,380
Hypoxia-selective inhibitors of DNA repair
CIHR · 2017 · Co-investigator
$259,381
Strategic configuration of cancer care services based on clinical, demographic and geographic considerations
CIHR · 2011 · Nominated PI
$347,338

All 4 grants and awards

115 publications.

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Leclerc C, Baker S, Jiang W, Mou B, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Chng N, Matthews Q, Benny A, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2026.01.012 PMID: 41580164

NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.

St-Laurent MP, Eigl BJ, Tyldesley S, Yuan R, Chang S, Vandekerkhove G, Black PC

European urology oncology2026

DOI: 10.1016/j.euo.2026.07.008 PMID: 42567733

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Kooyman A, Chang JS, Liu M, Jiang W, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R, Baker S

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.03.079 PMID: 40216089

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Baker S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, Schellenberg D, Clark H, Mou B, Liu M, Hsu F, Berrang T, Atrchian S, Bergman A, Chng N, Matthews Q, Chang JS, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.01.031 PMID: 39923903

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Olson R, Liu M, Bergman A, Mou B, Abraham H, Leclerc C, Carolan H, Schellenberg D, Jiang W, Alexander A, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Gautam D, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S, Baker S

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026

DOI: 10.1016/j.radonc.2026.111532 PMID: 42140754

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.

O'Reilly E, Johal E, Clark H, Mou B, Cereno RE, Liu M, Schellenberg D, Jiang W, Berrang T, Alexander A, Carolan H, Atrchian S, Dunne EM, Tyldesley S, Olson R, Baker S

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2025

DOI: 10.1016/j.radonc.2025.110948 PMID: 40409365

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Willmann J, Baker S, Chen H, Dee EC, Vlaskou Badra E, Christ SM, Mayinger M, Ahmadsei M, Adilovic S, Das S, Lechner L, Liu W, Liu M, Mou B, Berrang T, Schellenberg D, Tyldesley S, Erler D, Iyengar P, Redmond K, Ricardi U, Guckenberger M, Sahgal A, Olson R, Andratschke N

European journal of cancer (Oxford, England : 1990)2025

DOI: 10.1016/j.ejca.2025.115737 PMID: 40876085

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

Niazi T, Saad F, Tisseverasinghe S, Koul R, Thibault I, Chung PWM, Wakil G, Lock M, Delouya G, Bahoric B

The Lancet Oncology202529 citationsSenior author

DOI: 10.1016/s1470-2045(25)00351-1

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.

Olson R, Abraham H, Leclerc C, Benny A, Baker S, Matthews Q, Chng N, Bergman A, Mou B, Dunne EM, Schellenberg D, Jiang W, Chan E, Atrchian S, Lefresne S, Carolan H, Valev B, Tyldesley S, Bang A, Berrang T, Clark H, Hsu F, Louie AV, Warner A, Palma DA, Howell D, Barry A, Dawson L, Grendarova P, Walker D, Sinha R, Tsai J, Bahig H, Thibault I, Koul R, Senthi S, Phillips I, Grose D, Kelly P, Armstrong J, McDermott R, Johnstone C, Vasan S, Aherne N, Harrow S, Liu M

BMC cancer2024

DOI: 10.1186/s12885-024-11905-7 PMID: 38310262

Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.

Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, Tyldesley S, Wilson D, Bénard F

Cancer imaging : the official publication of the International Cancer Imaging Society2024

DOI: 10.1186/s40644-024-00752-1 PMID: 39210431

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2019

Subject: Prospective PhD student: Biomarkers Dear Professor Tyldesley, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3" (2019), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Scott Tyldesley

Research

Latest papers

Latest funding

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.

Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3

Hypoxia-selective inhibitors of DNA repair

Strategic configuration of cancer care services based on clinical, demographic and geographic considerations

Implementing Chemo SmartBook: A decision support tool for chemotherapy scheduling

Frequent collaborators

Devin Schellenberg

Alan Nichol

Michael Mckenzie

Mira Keyes

Robert Olson

Winkle Kwan

Marie-Pier St-Laurent

Gerard Morton

Kim Chi

David Palma

Eric Bouffet

Ute Bartels

David Hodgson

Jonathan Sussman

Peter Black

Martin Gleave

Nicholas Power

Arjun Sahgal

Laura Dawson

Eric Winquist

Rebecca Warburton

Christina Canil

Larry Goldenberg

Derek Tsang

Bernhard Eigl

Piotr Czaykowski

Michael Brundage

Lawrence Mbuagbaw

Stuart Peacock

Sebastien Hotte

Timothy Whelan

Theos Tsakiridis

James Wright

Do-Hoon Kim

Alexander Rauscher

Doris Howell